Browse the latest research summaries in the field of covid-19 for spinal cord injury patients and caregivers.
Showing 81-81 of 81 results
Frontiers in Molecular Biosciences, 2020 • December 17, 2020
There are no marketed and effective antiviral drug products or biologics available for the control of SARS-CoV-2, other than symptomatic clinical treatment strategies for COVID-19. The LT receptor anta...
KEY FINDING: Leukotrienes (LTs), particularly cysteinyl-leukotrienes (Cys-LTs) and their receptors, are identified as potential drug targets in modulating various aspects of COVID-19 pathology, including inflammation, thrombosis, vascular damage, and fibrotic response.